Aurobindo Pharma Stock Plunges 5% as US FDA Cites Nine Violations at Telangana Facility
Loading more articles...
Aurobindo Pharma Shares Plunge 5% After US FDA Flags 9 Issues at Telangana Unit
M
Moneycontrol•18-02-2026, 15:14
Aurobindo Pharma Shares Plunge 5% After US FDA Flags 9 Issues at Telangana Unit
•Aurobindo Pharma's shares dropped 5% to Rs 1,129.20 after the US FDA issued nine objections to its Unit 7 manufacturing facility in Telangana.
•The US FDA inspection, conducted from January 28 to February 10, highlighted serious irregularities including cleanliness, contamination, and data integrity issues.
•Key findings included equipment not cleaned for years, cross-contamination 380 times above limits, and the presence of E. Coli and bird droppings.
•The FDA also noted staff access to delete raw data, backdating of microbiology documents, and discrepancies in electronic and physical records.
•Further objections involved lack of proper equipment cleaning, inadequate computer control, missing manufacturing instructions, and inconsistent GMP training.
